Wan-Long Chuang
机构: Kaohsiung Medical University Hospital
每年引用次数
引用次数
引用: 25,722
H-指数: 72
I10-指数 : 367
出版物: 934
Safety and antiviral activity of pradefovir in patients with chronic hepatitis B virus infection: 48-week analysis of a phase 2 study
K. S. Lee , H. H. Lin , K. Q. Hu , Y. Xu
Journal of Clinical Virology 36
2006
Safety, tolerability and antiviral activity of pradefovir mesylate in patients with chronic hepatitis B virus infection: 48-week analysis of a phase 2 study
K. S. Lee , H. H. Lin , K. Q. Hu , Y. Xu
Journal of Hepatology 44
4
2006
Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment.
K. Agarwal , S. H. Ahn , M. Elkhashab , A. H. Lau
Journal of Viral Hepatitis 25 ( 11) 1331 -1340
23
2018
Amphotericin B up-regulates angiogenic genes in hepatocellular carcinoma cell lines.
Z. Y. Lin , W. L. Chuang , Y. H. Chuang
European Journal of Clinical Investigation 39 ( 3) 239 -245
16
2009
The epidemiology of TT virus (TTV) infection in a hepatitis C and B virus hyperendemic area of southern Taiwan.
Dai Cy , Huang Jf , Lin Zy , Hsieh My
Kaohsiung Journal of Medical Sciences 16 ( 10) 500 -509
4
2000
Sonographic study of portal vein thrombosis in hepatocellular carcinoma.
Lin Zy , Hsieh My , Jan Cm , Chuang Wl
Kaohsiung Journal of Medical Sciences 3 ( 1) 49 -55
4
1987
Immunological status in patients with chronic hepatitis B virus infection.
Hseih My , Liu Wj , Wang Ly , Chen Sc
Journal of the Formosan Medical Association 86 ( 11) 1193
2
1987
O-069 : Smaller Decreases in Bone Mineral Density in CHB Patients Receiving Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate Over 96 Weeks
Anuj Gaggar , Mustafa Celen , Mani Subramanian , John F Flaherty
춘·추계 학술대회 (KASL) 2017 ( 1) 49 -50
2017
O-063 : A Phase 3 Study Comparing Tenofovir Alafenamide (TAF) to Tenofovir Disoproxil Fumarate (TDF) in Patients with HBeAg-positive CHB patients
Norihiro Furusyo , Shalimar , Anuj Gaggar , Kosh Agarwal
춘·추계 학술대회 (KASL) 2017 ( 1) 46 -46
2017
PO-026 : Improvement in Renal Parameters in CHB Patients Treated with Tenofovir Alfenamide (TAF) versus Tenofovir Disoproxil Fumarate (TDF) over 96 Weeks
Anuj Gaggar , Aric Josun Hui , Jae Seok Hwang , Kosh Agarwal
춘·추계 학술대회 (KASL) 2017 ( 1) 96 -97
2017
IDDF2020-ABS-0061 Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB)
Henry Lik Yuen Chan , Young-Suk Lim , Wai Kay Seto , Qin Ning
Gut 69
2020
Diagnosis of Icteric-Type Hepatocellular Carcinoma by Fine Needle Aspiration
Jee-Fu Huang , Shinn-Cherng Chen , Liang-Yen Wang , Ming-Lung Yu
Acta Cytologica 50 ( 5) 531 -533
3
2006
IDDF2018-ABS-0108 Improved bone and renal safety at 1 year after switching from TENOFOVIR DISOPROXIL FUMARATE (TDF) to TENOFOVIR ALAFENAMIDE (TAF): results from 2 phase 3 studies in HBEAG-positive and HBEAG-negative patients with chronic hepatitis B (CHB)
Henry Lek-Yuen Chan , Calvin Pan , Maurizia Brunetto , Aric Josun Hui
Gut 67
3
2018
IMPACT OF LONG-TERM TREATMENT WITH CONTINUOUS TENOFOVIR ALAFENAMIDE (TAF) OR AFTER SWITCH FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)
Young-Suk Lim , Grace Lai-Hung C Wong , Sang Hoon Ahn , Wai-Kay Seto
HEPATOLOGY 78 S523 -S526
2023
Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB)
Y Lim , Henry Lik Yuen Chan , WKW Seto , Qing Ning
The 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting 2019
8
2019
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
Young-Suk Lim , Henry LY Chan , Sang Hoon Ahn , Wai Kay Seto
JHEP Reports 5 ( 10) 100847 -100847
3
2023
Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB)
Henry Lik Yuen Chan , Young-Suk Lim , Wai Kay Seto , Qin Ning
Gut 69 A75 -A76
2
2020
A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND TREATMENT REGIMENS OF VTP-300 COMBINED WITH LOW-DOSE NIVOLUMAB IN CHRONIC HEPATITIS B INFECTION
Henrik Sorensen , Tom Evans , Dereck Tait , Louise Bussey
HEPATOLOGY 78 S53 -S54
1
2023
EFFICACY AND SAFETY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH RENAL IMPAIRMENT: WEEK 24 RESULTS FROM A PHASE 2 OPEN-LABEL STUDY
Harry LA Janssen , Young-Suk Lim , Edward J Gane , Claire Fournier
Hepatology 70 306A -307A
1
2019
SAFETY AND EFFICACY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: WEEK 24 RESULTS FROM A PHASE 2 OPEN-LABEL STUDY
Young-Suk Lim , Pietro Lampertico , Ho S Bae , Wan Long Chuang
Hepatology 70
1
2019